UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2021
GUARDION HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38861 | 44-4428421 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
15150 Avenue of Science, Suite 200
San Diego, CA 92128
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (858) 605-9055
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $0.001 per share | GHSI | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01 | Other Events |
Nasdaq Compliance
As previously reported, on September 20, 2019, Guardion Health Sciences, Inc. (the “Company” or “we”) received notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the requirement to maintain a minimum bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with the Nasdaq Listing Rules, the Company was afforded 180 days, or until March 18, 2020, to regain compliance with the Bid Price Rule by evidence of a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Thereafter, the Company had been afforded a second 180-calendar day compliance period (which 180-day period was extended due to circumstances related to COVID-19), or until November 30, 2020, to regain compliance with the Bid Price Rule.
The Company was unable to regain compliance with the Bid Price Rule by November 30, 2020. Accordingly, on December 1, 2020, the Company received a letter from the Staff notifying it that its Common Stock would be subject to delisting from Nasdaq unless the Company timely appealed Nasdaq’s determination to a Nasdaq Listing Qualifications Panel (the “Panel”). The Company timely appealed Nasdaq’s determination to the Panel. On January 26, 2021, the Company received written notification that the Panel granted the Company an extension for continued listing through March 15, 2021.
On March 15, 2021, we received a letter from the Staff notifying us that we had regained compliance with the Bid Price Rule. The letter stated the staff had determined that for the prior 10 consecutive business days, the closing bid price of the Company’s common stock had been at $1.00 per share or greater and that accordingly, the Company had regained compliance under the Bid Price Rule, and that the matter was now closed.
On March 16, 2021, the Company issued a press release announcing the foregoing. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
Presentation
The Company is filing as Exhibit 99.2 to this Current Report on Form 8-K a presentation that will be given at Maxim Group’s Emerging Growth Virtual Conference on March 17, 2021.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
99.1 | Press Release, dated March 16, 2021 |
99.2 | Presentation, dated March 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUARDION HEALTH SCIENCES, INC. | ||
Date: March 16, 2021 | ||
By: | /s/ Bret Scholtes | |
Name: | Bret Scholtes | |
Title: | Chief Executive Officer |
Exhibit 99.1
Guardion
Health Sciences Regains Compliance with
Nasdaq Minimum Bid Price Rule
SAN DIEGO – March 16, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutritional supplements, medical foods, and medical devices, announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). On March 15, 2021, Guardion received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC (“Nasdaq”) stating that because Guardion’s Company’s common stock (the “Common Stock”) had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive trading days, its Common Stock had regained compliance with Nasdaq’s Minimum Bid Price Rule.
On September 20, 2019, the Company received notice from Nasdaq indicating that, based upon the closing bid price of the Common Stock, the Company no longer satisfied the Minimum Bid Price Rule. The Company was afforded 180 calendar days, or until March 18, 2020, to regain compliance with the Minimum Bid Price Rule. Thereafter, the Company was afforded a second 180 calendar day compliance period (which 180-day period was extended due to circumstances related to COVID-19), or until November 30, 2020, to regain compliance with the Minimum Bid Price Rule.
The Company was unable to regain compliance with the Minimum Bid Price Rule by November 30, 2020. Accordingly, on December 1, 2020, the Company received a letter from Nasdaq notifying it that its Common Stock would be subject to delisting from Nasdaq unless the Company timely requested a hearing before a Nasdaq Listing Qualifications Panel (the “Panel”). The Company timely requested the hearing.
Following the hearing, on January 26, 2021, the Company received written notification that the Panel had granted the Company an extension for continued listing through March 15, 2021. As referenced above, Nasdaq determined that the Company complied with the Panel’s decision and has regained compliance. Accordingly, Nasdaq has closed the compliance review.
About Guardion Health Sciences
Guardion Health Sciences, Inc. (NASDAQ: GHSI), is a clinical nutrition and diagnostics company. Guardion offers a portfolio of science-based, clinically supported nutrition, medical foods, and diagnostic products that support healthcare professionals, their patients, and consumers in achieving health goals. Guardion’s commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation of Guardion’s growing position within the eye care industry and the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
-1- |
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
scotta@coreir.com
Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
-2- |
Exhibit 99.2
]0!L#J31NQV%3<=B<_,..:CY9>>#]:3?C&"!30XSU
M!'M3N203VP=2&0$5A7>D*22@Q]*Z1I!D 'D]!BHG3(SC%%[;#.#N=)4%]ROG
M'X?EVK!N=&P V<$_=?&/P/:O49;5&ZC-9 C6OP7\2W^B6FJ6
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M-G-:I;O*N%N(O-C/]Y 1VGP;\1ZCXO74_$,]BUM- S>5%K\*M
MC.9HI(E_[Z=0/UKKH9HKF%)H)4EB<95T8,K#U!'6@!]%86I>,= TC7+;1K[4
M!#J%SM\J'RG;=N.U>0"!DCN:W:.EP"BBB@ HHHH *9-_J)/]T_RI],F_U$G^
MZ?Y4UN*6S,>E%)2UV'GBTHI*6D,6E%)2TABTHI*=2*04M(*6D-"TM(*<*104
MM)3A2&%+0**0Q:6D%+2&+110*"A12T4M2QA112T I:**0"T444%!2TE+2 *
M**6@84444 %%%% !1110 4444 %%%+2 ****!A2&EIIH #TKC?$[YN6'M78-
M7$>)#NO).>AK*J_=-*2]XY"\89-94N*TKQ?FK*DZFO+F]3U*:T*S]34+=:ED
M/.*C-8LW2(F%%.(IM(H4'UJ0,:0%ZVNY("-K<>F*UX9TN &4@-_=KG
MU/YU*LA7H2/I0G831OLQ7V-!?=6?!J&5"S_,/7O5Q&5UWH<@U6^P;$Z28/?B
MIEDJH.,C-.#XH&7ED[5*LO&,U067WJ9913$7!+M(%2B3 K/\P9ZU(LH/4TTP
M:-%)!4F_)ZUG"7 SFE^T=.:JY%C0\S%-\P>U4?M.>],,^3UHYAJ)ZU1117MG
M@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\U>,]#D\1_&76=,@)%Q(A:$#^)U@# 'ZXQ^-=W\$O%CWVE3>&[YB+NPYA
M#_>,6>5Y_NG]"/2L:#_DYN3_ 'V_])JJ_$73;GX?_$2R\6Z7'MM;J7>ZKT\S
M_EHA]F&3^?I1!I1C?9_G?0O*OV>_\ CRUW_KI#_)J<5:(D=*S9XV
@ZFA:T;
M':N'U%,[CGD
N?,A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M
G4GC/UKV;M113>UA=;GEGPM\':[X;
M\1Z]=ZM9"""YXA82H^_YR>BDD<8ZXKU.BBCHEV!ZMON>3_#WP5K^A?$77-6U
M&R6&RN!,(9/.1M^Z4,. 21P.^*[KQEX;3Q9X6O-(:01/* T4A&0CJ<@_3C'T
M-;U%)J\5'MH._O.1X+I'A7XO>'XO[&TNXCAT_<2)1-"T:YY)&X%P,^@ZUZCX
ML\'CQ=X/32+VYVW:*CI$6'AOXP^&XETG2
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MIT"PMM&M!